asthma
incid
highest
childhood
thereaft
decreas
remain
stabl
new
case
per
per
year
throughout
late
adolesc
adulthood
adult
popul
preval
activ
case
childhoodonset
asthma
coa
adultonset
asthma
aoa
approxim
equal
favor
aoa
reason
counterintuit
preval
ratio
includ
propens
coa
remit
frequent
aoa
greater
number
year
adulthood
accru
new
case
relev
clinic
manag
popul
diseas
burden
wide
rang
asthma
sever
mild
intermitt
sever
persist
sever
case
account
health
care
util
morbid
robust
populationbas
data
indic
around
half
adult
asthma
remain
suboptim
control
even
treat
current
avail
antiinflammatori
medic
adult
activ
asthma
sever
uncontrol
data
indic
need
novel
therapi
effect
sever
treatmentresist
case
asthma
account
major
morbid
mortal
health
care
util
emerg
evid
wide
varieti
microb
present
lower
airway
may
play
role
asthma
pathogenesi
suggest
manipul
airway
microbiom
may
novel
approach
toward
goal
studi
confirm
exist
infecti
etiolog
mediat
chlamydia
pneumonia
cp
possibl
viral
bacteri
fungal
microb
among
variou
infect
associ
asthma
oblig
intracellular
respiratori
pathogen
cp
particular
interest
associ
asthma
sever
treatment
resist
although
review
focus
cp
discuss
mycoplasma
pneumonia
mp
briefli
treatment
section
v
possibl
microb
cp
mp
implic
recurr
wheez
asthma
etiolog
may
serv
cofactor
viral
infect
certainli
appear
act
independ
asthmat
diseas
etiolog
asthma
remain
unknown
almost
certainli
multifactori
mani
trigger
asthma
attack
well
known
eg
allergen
viral
respiratori
infect
fume
cold
air
exercis
underli
mechan
expos
individu
develop
asthma
remain
elus
genet
studi
fail
locat
uniqu
asthma
gene
instead
point
toward
complex
multifactori
genet
environment
factor
current
popular
paradigm
hygien
hypothesi
posit
increas
incid
allergi
hayfev
eczema
asthma
note
recent
decad
associ
less
exposur
childhood
infect
bacteri
product
eg
endotoxin
emerg
evid
support
hygien
hypothesi
hayfev
eczema
asthma
appear
instead
relat
infect
throughout
life
cycl
host
lung
gut
microbiom
relat
asthma
activ
area
research
yet
must
point
studi
bacteri
rrna
may
fail
detect
cp
due
low
copi
number
sampl
problem
due
deep
tissu
intracellular
locat
speci
increas
number
studi
confirm
host
microbiom
signific
impact
risk
asthma
develop
studi
publish
hilti
colleagu
use
rna
clonelibrari
sequenc
show
compar
healthi
control
patient
asthma
significantli
pathogen
proteobacteria
fewer
bacteroidet
care
assess
healthi
control
asthmat
patient
confirm
presenc
bacteri
commun
howev
bacteri
burden
significantli
greater
patient
asthma
healthi
control
microbi
burden
even
greater
asthmat
greater
bronchial
reactiv
upon
methacholin
challeng
patient
show
mark
improv
bronchial
reactiv
methacholin
week
clarithromycin
importantli
greater
bronchial
reactiv
also
correl
greater
rel
abund
member
certain
bacteri
commun
known
exhibit
characterist
contribut
asthma
pathophysiolog
includ
speci
capabl
induc
nitric
oxid
reductas
produc
sphingolipid
abil
metabol
steroid
compound
recent
studi
show
old
infant
posit
oropharynx
cultur
streptococcu
pneumonia
moraxella
catarrhali
haemophilu
influenza
show
increas
suscept
develop
childhood
asthma
anoth
recent
studi
conclud
nasopharyng
microbiom
within
first
year
life
determin
infect
spread
lower
airway
predict
sever
accompani
inflammatori
symptom
well
risk
futur
asthma
develop
author
show
earli
asymptomat
colon
nasopharynx
streptococcu
strong
asthma
predictor
author
also
demonstr
antibiot
usag
disrupt
asymptomat
colon
prevent
asthmat
onset
find
support
hypothesi
colon
develop
airway
certain
microb
viral
bacteri
significantli
alter
airway
architectur
overal
immun
function
influenc
airway
respond
varieti
insult
find
also
suggest
antimicrobi
agent
may
repres
effect
therapeut
tool
potenti
curtail
durat
sever
asthma
exacerb
initi
varieti
microb
expos
limit
hygien
hypothesi
regard
microbiom
studi
cite
specif
target
cp
mp
upper
airway
studi
specif
test
atyp
organ
report
posit
detect
intracellular
detect
cp
adenoid
tissu
symptomat
children
extrem
common
rais
question
regard
potenti
cpmicrobiom
interact
infect
earli
life
act
either
induc
wheez
protector
develop
allerg
diseas
asthma
mani
young
children
wheez
episod
associ
earlylif
respiratori
infect
infect
like
associ
wheez
episod
includ
respiratori
syncyti
viru
rsv
human
rhinoviru
hrv
human
metapneumoviru
parainfluenza
virus
coronaviru
hygien
hypothesi
propos
infant
frequent
earli
life
infect
may
protect
asthma
certainli
appear
case
infant
wheez
episod
respiratori
infect
diminish
child
age
howev
other
earlylif
wheez
episod
may
mark
begin
asthma
regard
establish
asthma
mani
type
viral
respiratori
infect
shown
signific
influenc
fact
viral
respiratori
infect
diagnos
episod
asthma
children
adult
question
remain
factor
determin
viral
respiratori
infect
provok
onset
chronic
asthma
factor
appear
includ
type
viru
viral
infecti
dose
well
host
suscept
factor
lead
inflamm
airway
cellular
infiltr
neutrophil
eosinophil
presenc
allergen
airway
interact
host
immun
system
combin
host
pathogen
factor
result
airway
inflamm
hyperrespons
outcom
could
asthma
could
cp
play
key
role
complex
scenario
clue
answer
question
found
secondari
analysi
data
communitybas
pediatr
viral
respiratori
infect
studi
identifi
viral
infect
exacerb
one
hundr
eight
children
asthma
symptom
complet
longitudin
studi
exacerb
record
cp
pcr
cpspecif
secretori
iga
cpsiga
antibodi
measur
exacerb
asymptomat
period
cp
pcr
detect
similar
symptomat
asymptomat
episod
v
respect
children
report
multipl
exacerb
remain
cp
pcr
posit
p
suggest
chronic
infect
cpsiga
antibodi
seven
time
greater
subject
report
four
exacerb
compar
report
one
p
author
suggest
immun
respons
chronic
cp
infect
may
interact
allerg
inflamm
increas
asthma
symptom
notabl
mp
found
import
studi
emerg
evid
link
cp
infect
de
novo
asthma
asthma
onset
duringaft
acut
lower
respiratori
tract
infect
previous
nonasthmat
individu
also
refer
infecti
asthma
syndrom
asthma
sever
section
review
known
cp
asthma
initi
sever
multipl
experiment
establish
mechan
might
mediat
associ
therapeut
implic
review
section
v
de
novo
wheez
acut
lower
respiratori
tract
infect
remark
common
wheez
episod
appear
resolv
without
chronic
sequela
sometim
chronic
asthma
develop
surprisingli
clinic
studi
report
asthma
onset
acut
respiratori
ill
exceedingli
common
adultonset
asthma
case
strong
tempor
associ
respiratori
infect
asthma
onset
confirm
populationbas
studi
reliabl
way
establish
whether
specif
respiratori
pathogen
initi
asthma
would
perform
larg
longterm
prospect
microbiolog
clinic
cohort
studi
gener
nonasthmat
popul
studi
would
expens
yet
undertaken
second
approach
would
perform
prospect
studi
select
nonasthmat
patient
exhibit
risk
factor
asthma
clinic
set
select
risk
factor
inde
identifi
peopl
higher
likelihood
develop
infecti
asthma
syndrom
type
studi
might
feasibl
characterist
associ
cpmp
biomarkerposit
infecti
asthma
includ
patient
sever
treatmentresist
asthma
exhibit
neutrophil
airway
inflamm
test
pcr
posit
cp
mp
howev
note
current
test
set
test
definit
diagnos
benefit
maxim
azithromycin
treatment
factor
predict
risk
nonasthmat
develop
infecti
asthma
syndrom
includ
previou
histori
selflimit
lower
respiratori
tract
ill
acut
bronchiti
often
wheez
andor
pneumonia
risk
factor
may
oper
poorli
understood
time
time
period
hahn
et
al
collect
prospect
cp
microbiolog
test
clinic
data
patient
de
novo
wheez
nine
subject
exhibit
acut
bronchit
ill
one
communityacquir
pneumonia
met
serolog
criteria
acut
primari
n
secondari
n
cp
infect
nine
patient
acut
bronchiti
wheez
four
improv
without
treatment
five
progress
chronic
asthma
patient
pneumonia
treat
tradit
short
cours
macrolid
resolut
pneumon
infiltr
yet
develop
chronic
bronchiti
cp
isol
cultur
sputum
month
later
type
studi
replic
rais
sever
question
cp
well
known
caus
protean
manifest
acut
respiratori
ill
observ
suggest
cp
may
also
capabl
caus
protean
manifest
chronic
respiratori
condit
eg
asthma
chronic
bronchiti
copd
review
wherea
cp
infect
patient
de
novo
wheez
resolv
acut
ill
without
treatment
other
develop
chronic
sequela
identif
underli
protect
promot
factor
might
help
address
current
asthma
pandem
establish
cpassoci
asthma
link
increas
sever
sever
studi
cook
et
al
first
identifi
cp
biomark
refer
brittl
asthma
asthma
hard
control
sever
averag
accumul
bodi
evid
support
associ
cp
infect
asthma
sever
steroid
resist
asthma
multipl
mechan
support
biolog
plausibl
associ
review
exposur
cigarett
smoke
establish
factor
tie
steroid
resist
asthma
similar
cigarett
smoke
cp
induc
pulmonari
bronchial
epitheli
ciliostasi
addit
cp
infect
alveolar
macrophag
lung
monocyt
lead
enhanc
product
infect
human
bronchial
smooth
muscl
cell
produc
basic
fibroblast
growth
factor
potenti
effect
bronchial
hyper
reactiv
lung
remodel
yet
thoroughli
investig
chronic
infect
expos
tissu
chlamydi
heat
shock
protein
bacteri
lipopolysaccharid
lp
associ
increas
inflamm
asthma
review
lastli
cpspecif
ige
demonstr
strongli
associ
sever
persist
asthma
case
chronic
respiratori
ill
children
sever
enough
justifi
undergo
bronchoscopi
wherea
exposur
recogn
allergen
mitig
exposur
unrecogn
bacteri
allergen
may
result
chronic
unrel
exposur
could
contribut
sever
may
prove
difficult
even
imposs
unravel
exactli
mechan
contribut
produc
infecti
asthma
phenotyp
regard
involv
cp
asthma
pathogenesi
controversi
whether
associ
causal
coincident
settl
two
way
patient
diagnos
asthma
treat
aim
evalu
effect
antibiot
amelior
asthma
symptom
compar
untreat
placebo
control
anim
model
perform
evalu
role
cp
asthma
initi
andor
exacerb
experiment
anim
inocul
studi
may
help
elucid
mechan
underli
cp
asthma
pathogenesi
past
three
decad
anim
model
asthma
extens
util
elucid
mechan
diseas
determin
activ
gene
interest
investig
cellular
pathway
predict
safeti
efficaci
variou
drug
consid
asthma
treatment
initi
murin
model
chlamydi
lung
infect
carri
adult
mice
seem
close
repres
acut
human
asthma
studi
util
mous
pneumon
biovar
c
trachomati
mopn
sinc
well
known
natur
mous
pathogen
would
therefor
repres
best
choic
investig
hostpathogen
interact
context
earli
studi
record
extens
lung
consolid
day
airway
infect
found
signific
airway
inflamm
character
neutrophil
infiltr
airway
exud
earli
studi
also
confirm
multipl
reinfect
requir
induc
symptom
chronic
asthma
immun
respons
contribut
subsequ
activ
macrophag
necessari
clear
infect
recent
mani
studi
util
neonat
mous
model
infecti
asthma
sinc
earli
studi
demonstr
neonat
cell
immun
respons
mice
human
skew
toward
cellular
phenotyp
result
placent
immun
pressur
cell
much
less
effect
immun
respons
compar
adult
counterpart
horvat
et
al
later
demonstr
neonat
chlamydi
lung
infect
induc
mix
tcell
respons
drive
allerg
airway
diseas
aad
use
balbc
mous
model
ovalbumin
induc
aad
work
group
confirm
chlamydi
infect
neonat
infant
adult
mice
exacerb
develop
hallmark
featur
asthma
ovalbumininduc
allerg
airway
diseas
model
notabl
featur
includ
increas
mucussecret
cell
number
express
airway
hyperrespons
studi
lab
confirm
earlylif
chlamydi
airway
infect
induc
immun
respons
airway
eosinophilia
neutrophilia
perman
alter
lung
structur
function
concomit
enhanc
sever
allerg
airway
diseas
later
life
confirm
neonat
infect
mice
never
clear
infect
show
dissemin
liver
spleen
peripher
circul
develop
chlamydiaspecif
ige
antibodi
infect
neonat
adult
control
recent
hansbro
et
al
complet
work
use
bone
marrow
chimera
reconstitut
clearli
demonstr
infant
lung
infect
result
last
alter
hematopoiet
cell
lead
increas
sever
aad
later
adult
life
signific
studi
kaiko
et
al
demonstr
infect
bone
marrowderiv
dentrit
cell
bmdc
promot
immun
airway
hyperreact
mous
model
intratrach
passiv
transfer
infect
bmdc
uninfect
control
bmdc
balbc
mice
result
increas
bal
fluid
anim
also
show
signific
increas
airway
resist
reduct
airway
complianc
compar
uninfect
counterpart
hallmark
asthma
confirm
role
chlamydi
infect
asthma
initi
patholog
least
mice
set
experi
et
al
demonstr
adopt
transfer
lung
dendrit
cell
cp
infect
mice
uninfect
mice
produc
eosinophil
airway
inflamm
challeng
exogen
allergen
human
serum
albumin
dose
time
taken
togeth
find
suggest
plausibl
cp
infect
sole
lung
dendrit
cell
may
suffici
induc
asthma
phenotyp
may
demonstr
characterist
infecti
allerg
anim
model
studi
ad
significantli
understand
mechan
involv
inflammatori
process
chlamydi
infect
lead
asthma
initi
exacerb
also
appear
damag
caus
chlamydi
airway
infect
time
lead
exagger
airway
repair
airway
wall
remodel
major
featur
type
respons
includ
epitheli
cell
shed
goblet
cell
hyperplasia
hypertrophi
hyperplasia
airway
smooth
muscl
bundl
basement
membran
thicken
increas
vascular
densiti
angiogenesi
function
mechan
consequ
type
aberr
repair
lead
bronchial
wall
thicken
uncoupl
bronchial
wall
surround
parenchyma
significantli
enhanc
airway
narrow
sever
obstruct
type
airway
damag
might
prove
irrevers
even
longterm
inhal
steroid
treatment
moreov
well
document
corticosteroid
use
drive
cp
persist
state
activ
replic
sinc
corticosteroid
neg
impact
sever
aspect
cellmedi
immun
favor
shift
toward
immun
respons
shift
respons
significantli
imped
abil
host
erad
intracellular
pathogen
like
cp
may
lead
releas
exacerb
inflammatori
process
also
evid
cp
infect
may
promot
airway
remodel
decreas
ratio
secret
inflammatori
cell
alter
cellular
respons
corticosteroid
see
fig
summari
establish
suspect
mechan
wherebi
cp
infect
may
contribut
asthma
pathogenesi
histor
asthma
categor
either
allerg
nonallerg
distinct
put
question
earli
earli
report
associ
cp
asthma
find
independ
associ
cp
biomark
clinic
allergi
asthma
yet
clinic
set
overlap
atopi
cp
infect
anim
model
describ
earlier
indic
cp
promot
asthma
atopi
thu
absolut
distinct
two
categori
indic
differ
underli
etiolog
may
warrant
macrolid
treatment
trial
examin
subgroup
respons
one
approach
examin
predict
valu
subgroup
asthma
also
character
either
eosinophil
neutrophil
base
cellular
composit
respiratori
secret
bronchoalveolar
lavag
fluid
balf
simpson
et
al
perform
rct
macrolid
clarithromycin
sever
refractori
asthma
adult
report
overal
benefit
group
whole
howev
posit
effect
prespecifi
subgroup
patient
neutrophil
asthma
defin
sputum
neutrophil
number
predict
power
find
limit
sinc
unclear
whether
sputum
composit
stabl
time
sever
refractori
asthma
asthma
matter
major
peopl
asthma
well
control
convent
guidelinebas
antiinflammatori
treatment
mainli
inhal
steroid
sometim
combin
inhal
longact
bronchodil
nevertheless
signific
minor
peopl
asthma
well
control
guidelin
treatment
proport
peopl
refractori
asthma
asthma
respons
guidelin
therapi
estim
contribut
refractori
asthma
asthma
morbid
mortal
consider
greater
sever
asthma
case
account
asthma
morbid
health
care
cost
patient
overlap
syndrom
asthma
copd
includ
number
peopl
refractori
diseas
increas
significantli
variou
novel
therapi
consider
refractori
asthma
macrolid
appear
one
promis
metaanalysi
random
control
trial
rct
macrolid
long
term
manag
asthma
adult
children
found
posit
effect
peak
expiratori
flow
rate
pefr
measur
pulmonari
function
asthma
symptom
asthma
qualiti
life
aql
airway
hyper
respons
ahr
forc
expiratori
flow
rate
updat
cochran
review
rct
report
posit
benefit
asthma
symptom
aql
ahr
pefr
analyz
joint
european
respiratori
societyamerican
thorac
societi
ersat
guidelin
sever
asthma
recommend
use
macrolid
condit
recommend
low
qualiti
evid
ersat
guidelin
state
recommend
place
rel
higher
valu
prevent
develop
resist
macrolid
antibiot
rel
lower
valu
uncertain
clinic
benefit
inconsist
find
metaanalys
along
uncertainti
surround
clinic
benefit
macrolid
underscor
need
higher
qualiti
evid
section
add
evid
includ
metaanalys
review
known
macrolid
side
effect
includ
clinic
consequ
resist
suggest
research
approach
obtain
better
evid
conclud
provision
recommend
clinician
may
approach
patient
newonset
uncontrol
andor
refractori
asthma
ask
macrolid
treatment
current
evid
asthma
treatment
limit
due
select
bia
initi
research
clinician
even
asthma
patient
research
bia
academ
literatur
replet
asthma
efficaci
studi
lack
generaliz
efficaci
trial
current
asthma
treatment
guidelin
base
systemat
exclud
peopl
asthma
encount
gener
clinic
popul
pragmat
effect
trial
minim
exclus
abl
provid
evid
applic
gener
popul
clinician
bia
recent
trial
azithromycin
acut
exacerb
asthma
azalea
notabl
patient
exacerb
elig
enrol
primarili
receiv
antibiot
treat
clinician
accompani
editori
specul
one
possibl
reason
neg
result
azalea
clinician
somehow
abl
identifi
treat
like
candid
make
inelig
research
may
azalea
exampl
asthma
research
made
less
inform
due
nonresearch
clinician
behavior
patient
bia
hahn
et
al
perform
pragmat
trial
azithromycin
asthma
azmat
like
candid
exclud
random
unanticip
event
occur
azmat
internetbas
trial
peopl
sever
refractori
asthma
identifi
like
candid
contact
pi
enrol
upon
learn
chanc
receiv
placebo
opt
random
favor
receiv
compar
azithromycin
prescript
person
clinician
rather
lose
data
openlabel
ol
group
studi
protocol
alter
includ
third
ol
arm
random
result
similar
azalea
neg
see
fig
howev
ol
subject
exhibit
larg
unpreced
improv
symptom
qualityoflif
qol
persist
long
treatment
complet
fig
ol
group
random
result
appear
metaanalysi
rct
nevertheless
strongli
suggest
futur
macrolid
rct
focu
sever
end
asthma
spectrum
also
recommend
other
prefer
engag
patient
popul
unlik
want
opt
random
macrolid
mechan
action
asthma
thought
directli
antiinflammatori
indirectli
antiinflammatori
ie
antimicrobi
difficult
invok
direct
antiinflammatori
macrolid
effect
respons
larg
clinic
benefit
persist
month
treatment
complet
antimicrobi
effect
specif
respiratori
pathogen
gener
lung
microbiom
remain
like
possibl
circumstanti
evid
suggest
macrolid
treatment
effect
may
least
part
attribut
antimicrobi
action
chronic
atyp
infect
issu
mean
settl
requir
research
may
challeng
given
select
bias
note
coupl
like
low
sensit
lung
sampl
lead
fals
neg
diagnosi
exampl
chronic
cp
lung
infect
azithromycin
gener
well
toler
wide
use
varieti
acut
respiratori
ill
concern
advers
effect
azithromycin
includ
develop
antibiot
resist
sudden
cardiac
death
hear
loss
effect
host
mcrobiom
develop
resist
possibl
whenev
antibiot
use
azithromycin
except
howev
report
patient
harm
resist
organ
cardiorespiratori
trial
perform
date
rather
detect
clinic
effect
azithromycin
trial
decreas
incid
sinus
acut
bronchiti
pneumonia
less
use
antibiot
sudden
cardiac
death
attribut
azithromycin
prescript
high
cardiac
risk
patient
plausibl
document
epidemiolog
studi
medicaid
popul
tennesse
risk
also
present
quinolon
levofloxacin
subsequ
populationbas
studi
averag
risk
popul
show
increas
risk
sudden
death
mild
hear
loss
report
excess
heart
diseas
subject
random
mg
azithromycin
weekli
month
hear
test
chang
lead
discontinu
azithromycin
occur
sever
copd
subject
random
mg
azithromycin
daili
year
clinic
signific
hear
test
chang
unclear
notabl
like
daili
azithromycin
dose
unnecessari
may
lead
increas
advers
event
prolong
halflif
azithromycin
within
cell
includ
within
immun
system
cell
allow
weekli
dose
may
prefer
daili
dose
target
either
immun
cell
intracellular
pathogen
cp
although
larg
specul
time
appear
macrolid
effect
lung
microbiom
may
potenti
harm
help
asthma
segal
et
al
report
week
treatment
azithromycin
alter
bacteri
burden
reduc
also
observ
signific
reduct
certain
proinflammatori
cytokin
might
explain
nonspecif
antiinflammatori
effect
proven
benefici
copd
asthma
publish
find
slater
et
al
specif
evalu
azithromycin
effect
lung
microbiom
reveal
signific
reduct
bacteri
rich
airway
microbiota
importantli
reduct
signific
three
pathogen
genera
pseudomona
haemophilu
staphylococcu
overal
avail
data
suggest
azithromycin
treatment
sever
asthma
controversi
may
benefit
confirm
atyp
bacteri
infect
resist
advers
event
includ
sudden
death
hear
loss
chang
host
microbiom
monitor
futur
pragmat
trial
protean
manifest
chronic
cp
infect
may
includ
asthma
chronic
bronchiti
copd
overlap
syndrom
asthma
copd
argu
favor
pragmat
trial
broad
inclus
criteria
includ
patient
lung
multimorbid
least
nine
domain
distinguish
pragmat
effect
trial
explanatori
efficaci
trial
tabl
context
futur
rct
macrolid
asthma
propos
import
pragmat
domain
broad
elig
account
protean
clinic
manifest
chronic
reactiveobstruct
lung
diseas
cp
infect
discuss
previous
comprehens
patientcent
primari
outcom
asthma
exacerb
current
popular
choic
primari
outcom
clinic
relev
howev
exacerb
one
mani
outcom
import
asthma
patient
compar
exacerb
asthma
qualityoflif
qol
comprehens
measur
patientimport
outcom
qol
includ
limit
advers
effect
exacerb
patient
wellb
qol
proven
robust
sole
pragmat
macrolideasthma
trial
perform
date
fig
mani
patient
pragmat
trial
significantli
decreas
asthma
qol
studi
entri
larg
import
improv
qol
azithromycin
experi
exacerb
signific
subgroup
would
either
possibl
inelig
inclus
count
success
trial
use
exacerb
primari
outcom
pragmat
trial
primarili
ask
treatment
work
explanatori
trial
primarili
ask
mechan
address
target
groupsmechan
pragmat
trial
macrolid
desir
possibl
secondari
aim
specifi
priori
hypothes
coupl
subgroup
analys
recommend
studi
wide
array
biomark
use
approach
notabl
rct
macrolid
perform
andor
macrolid
recommend
treatment
mani
chronic
lung
condit
diffus
panbronchiol
cystic
fibrosi
bronchiectasi
copd
posttranspl
bronchiol
obliteran
plan
trial
test
effect
azithromycin
patient
overlap
syndrom
asthmacopd
time
add
asthma
grow
list
chronic
respiratori
condit
evalu
robust
macrolid
rct
pragmat
natur
meantim
patient
sever
uncontrol
andor
refractori
asthma
newonset
asthma
increasingli
search
internet
new
inform
sometim
better
inform
doctor
current
evid
regard
macrolid
asthma
hahn
person
observ
pend
robust
data
asthma
rct
yet
perform
practic
clinician
respond
patient
request
macrolid
treatment
state
ersat
guidelin
sever
asthma
recommend
use
macrolid
albeit
caveat
evid
recommend
weak
provision
inform
guidelin
pulmonolog
research
group
state
recommend
macrolid
treatment
confirm
diagnos
atyp
lung
infect
practic
standpoint
recommend
limit
treatment
undergon
bronchoscopi
even
diagnost
sensit
like
less
perfect
due
sampl
issu
discuss
earlier
recommend
met
resist
patient
read
understood
evid
hahn
person
commun
offer
third
altern
recommend
repeat
word
word
conclus
sole
practicebas
pragmat
trial
azithromycin
asthma
conduct
date
pend
random
trial
given
rel
safeti
azithromycin
signific
diseas
burden
sever
refractori
asthma
prescrib
prolong
azithromycin
therapi
patient
uncontrol
asthma
may
consid
manag
clinician
particularli
patient
fail
respond
convent
treatment
altern
institut
immunomodulatori
agent
interest
clinician
other
wish
inform
patient
experi
scientif
evid
treatment
altern
refer
book
subject
evid
support
complex
interact
host
geneticsimmun
respons
environment
factor
eg
viral
infect
microbiom
develop
exacerb
sever
asthma
emerg
evid
anim
model
human
studi
point
chlamydia
pneumonia
cp
key
player
complex
scenario
futur
research
requir
unravel
quantit
contribut
cp
asthma
pathogenesi
pragmat
treatment
trial
recommend
investig
therapeut
implic
